Investors: Press Release
AVITA Medical Limited Implementation of the Scheme of Arrangement to Redomicile from Australia to the United States of America
In accordance with the Scheme, all ordinary shares in the Company have today been transferred to
As contemplated by the Scheme, the Scheme consideration was today issued to eligible shareholders of the Company in the form of:
- Avita US CHESS Depositary Interests (CDIs), which commenced trading on a deferred settlement basis on ASX on
24 June 2020and will commence trading on a normal settlement basis on 30 June 2020(under the Company’s existing ticker code, “AVH”); or
- Shares of common stock in Avita US, trading in respect of which is currently anticipated to commence on the
NASDAQ Stock Market LLC(NASDAQ) on 1 July 2020(under the Company’s existing ticker code, “RCEL”).
In relation to Avita US CDIs issued under the Scheme, holding statements (to issuer sponsored holders) and confirmation advices (to CHESS holders) will be despatched to eligible shareholders on
Avita US, as the successor to the Company, will be subject to the reporting requirements of the
Further details in relation to the Scheme and its implementation (including Scheme consideration) are set out in the Scheme Booklet dated
Authorised for release by the Chief Financial Officer of
AVITA Medical’s first
In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in
To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This announcement includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this announcement include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this announcement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this announcement. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this announcement speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.
Phone +1 615 414 8668
Phone +61 (0)3 9620 3333
Mobile +61 (0)411 402 737
Phone +1 415 202 5678
Chief Financial Officer
Phone +1 661 367 9178